Billionaire-backed TCR startup scores its first marquee industry alliance,SAN FRANCISCO — A Bay Area startup out to create a next-gen player in TCRs has just hit a key milestone following its recent debut, inking its first big alliance with a big-name pharma while also bringing in some added insights from clinical operations that can help shape their work.
Billionaire-backed TCR startup scores its first marquee industry alliance
SAN FRANCISCO — A Bay Area startup out to create a next-gen player in TCRs has just hit a key milestone following its recent debut, inking its first big alliance with a big-name pharma while also bringing in some added insights from clinical operations that can help shape their work.
Nine ways small businesses can reduce IT costs,From subscriptions to printing, small businesses can cut back on a variety of areas to cope with economic turmoil Tags:BUSINESSBusiness strategyitpro.co.uk
Intense solar storm supercharges auroras over UK and more (photos),The sky was ablaze as far south as London in the UK last night, and more auroral beauty is expected to come. Tags:Auroraspace.com
Kamelot’s Thomas Youngblood discusses the evolution of a bona-fide Florida metal institution and the guitar strategies that challenge his audience,Kamelot have made a spectacular return with The Awakening, reestablishing the Sunshine State veterans as champions of guitar-forward, progressive power metal Tags:guitarworld.comkamelotThomas Youngblood
Giant's new Trance X Advanced E+ Elite is their lightest e-MTB ever, but it still packs full-power,Giant enters the lightweight e-MTB with their full-power Trance X Advanced E+ Elite and it's loaded with tech Tags:bikeperfect.com
David Harris condemns alleged armed assault in Weymouth,WEYMOUTH Town Council leader David Harris condemned an alleged assault by teenagers which reportedly involved a knife and a hammer in the town. Tags:Dorset Echodorsetecho.co.ukNews
'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023,'As the market has turned': Enveda secures $68M to move revised pipeline into the clinic in 2023,Enveda Biosciences will enter the clinic next year with at least one of its three main programs thanks to a $68 million boost in financing — about $55 million via equity and the remainder debt. Founded by an early employee at AI startup Recursion Pharmaceuticals, Enveda has adjusted its priorities Tags:AIBusiness and HealthEndpoints Newsendpts.comfinancingNewspodcastsstartups
'Banding together': 50 female biotech executives lay out plans for board diversity, new companies and mentoring founders,Earlier this month, during the Silicon Valley Bank meltdown, Angie You recalled the speed with which female biotech CEOs were helping each other connect with bankers, get their wires through and assuage concerns during a financial implosion. This past weekend, 50 of about 125 women who are part of that Tags:Business & HealthEndpoints Newsendpts.comPEOPLE
'Moonshot' at liver cell therapy biotech Ambys Medicines comes to an end,Ambys Medicines, backed by Third Rock Ventures and a partner to Takeda, closed its doors in recent months without a big public disclosure, but multiple employees flashed signals on a networking site. The South San Francisco biotech planned to make a hepatocyte replacement cell therapy for liver disease, but per Tags:Business & HealthCellGene TxEndpoints Newsendpts.comPEOPLEstartups
'Perfect time': SIGA's CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play,In the 1990s, Phil Gomez recalls the UK government launching what would be akin to a quasi-Operation Warp Speed in today's parlance, as the region was facing high cases of meningitis C in children under the age of 5. The chemical engineer by training was working at North American Vaccine Tags:Business & HealthEndpoints Newsendpts.comPeer Review
'Smooth and very much on track': Eisai reports first shipments of Leqembi,Eisai and Biogen began shipping out doses of their newly approved Alzheimer’s drug Leqembi ahead of schedule last month, according to Eisai’s US chairman and CEO Ivan Cheung. If all goes according to plan, the chief executive hopes to achieve full approval and expand access to Leqembi later this year, Tags:Business & HealthEndpoints Newsendpts.comPharma
'Very real' headwinds: With leaner staff, cancer vaccine maker searches for help,Cancer vaccine biotech IMV said it will look at “strategic alternatives following a review of its business” as the Canadian company continues clinical trials. The Nova Scotia and Cambridge, MA biotech laid off about one-third of its staff last fall to “maximize shareholder value.” Now, IMV wants to “realize its Tags:Business & HealthEndpoints Newsendpts.comfinancingR&D
‘Harder to find homes’: Latest wave of biotech layoffs could test the industry,A quarters-long flurry of layoffs has caused thousands of workers in life sciences to go hunting for their next position sooner than expected, and the latest wave could make it more difficult to get new offers in hand in short order. At least three dozen biotechs let employees go so Tags:Business & HealthEndpoints Newsendpts.comIn FocusPEOPLEpremium
‘Siloing is just so outdated’: New $350M VC fund aims to digitize life sciences,As technology increasingly helps find drug targets, enhance the diagnosis of diseases, speed up the testing of new therapeutics and essentially angle its way into every corner of life sciences, entrepreneurs will need a new type of VC firm. At least, that's the thinking behind the latest fund to drop. Tags:Business & HealthEndpoints Newsendpts.comfinancingstartups
#ASH22 Recap: Leading hematology experts talk top readouts; Fireside chat with Novo Nordisk's Ludovic Helfgott; More,#ASH22 Recap: Leading hematology experts talk top readouts; Fireside chat with Novo Nordisk's Ludovic Helfgott; More,The American Society of Hematology wraps up every year with one of the biggest conferences in the biopharma industry. It’s a place where lots of new innovations in hematology — from leukemia to multiple myeloma to hemophilia and more — are presented, discussed, questioned or even celebrated. It’s also a Tags:Business and HealthCellGene TxdiscoveryEndpoints Newsendpts.comNewspremiumR and DTrending
#ASH22 roundup: CSL shows two years of data in $3.5M hemophilia gene therapy; Syndax shows 30% CR rate from March data cut,#ASH22 roundup: CSL shows two years of data in $3.5M hemophilia gene therapy; Syndax shows 30% CR rate from March data cut,NEW ORLEANS — CSL Behring made headlines last month after the FDA gave approval to the biotech for its hemophilia B gene therapy with a $3.5 million price tag. And at ASH, the biotech is reporting six months' more durability data that show their treatment continues to work. The company's drug Tags:Business and HealthEndpoints Newsendpts.comNewspopularR and D
#ASH22: ALX Oncology reports complete response with anti-CD47 candidate in combo trial,#ASH22: ALX Oncology reports complete response with anti-CD47 candidate in combo trial,NEW ORLEANS — ALX Oncology said it's getting some promising, if very early, signals from a small trial that could give its CD47 drug new life. The biotech released data from a Phase I dose-escalation study Monday, showing that three patients with newly diagnosed acute myeloid leukemia (AML) all saw a Tags:Business and HealthEndpoints Newsendpts.comNewsR and DTrending
#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS,#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS,NEW ORLEANS — As the last six abstracts were presented at the American Society of Hematology on Tuesday, BeiGene sought to establish that its BTK inhibitor is now practice-changing. The pharma released more data from its Phase III ALPINE trial Tuesday morning, showing that Brukinsa (zanubrutinib) beat Imbruvica (ibrutinib) head to Tags:Business and HealthEndpoints Newsendpts.comNewsR and D
#ASH22: Cogent touts data on small subset of rare disease patients in bid to compete with Blueprint,#ASH22: Cogent touts data on small subset of rare disease patients in bid to compete with Blueprint,NEW ORLEANS — Cogent Biosciences delivered an early look at efficacy and safety on its advanced systemic mastocytosis drug candidate, which the biotech hopes will help it eke out a space in the treatment landscape, currently covered by Blueprint Medicines’ approved Ayvakit. Investors sent shares $COGT up about 8% Monday Tags:Business and HealthEndpoints Newsendpts.comFeaturedNewsR and D
#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review,#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review,NEW ORLEANS — Following up on two subsets presented Saturday, Eli Lilly’s Loxo Oncology fleshed out the data on its non-covalent BTK inhibitor pirtobrutinib in patients with mantle cell lymphomas as an FDA decision looms on whether the daily pill can enter a field covered by three BTK rivals. Loxo Tags:Business and HealthEditor's PicksEndpoints Newsendpts.comNewsR and D
#ASH22: Novartis PNH drug tops AstraZeneca with what's described as 'practice-changing' potential,#ASH22: Novartis PNH drug tops AstraZeneca with what's described as 'practice-changing' potential,NEW ORLEANS — Novartis showed hematologists and industry insiders Tuesday morning just how well iptacopan beat AstraZeneca’s two standard-of-care medicines for a rare blood disease – nailing both primary endpoints, while zero patients on Soliris and Ultomiris achieved either. The Swiss Big Pharma and its trial investigators presented the fleshed-out Tags:Business and HealthEditor's PicksEndpoints Newsendpts.comNewsPharmaR and D
#ASH22: Regeneron claims it has set a 'new benchmark' in follicular lymphoma,#ASH22: Regeneron claims it has set a 'new benchmark' in follicular lymphoma,NEW ORLEANS — Regeneron gave researchers a first look at interim results from its Phase II study of a CD20xCD3 bispecific antibody in patients with relapsed/refractory follicular lymphoma, with a planned regulatory filing on tap for next year as it seeks to catch up with rival Roche. Trial investigators said Tags:Business and HealthEndpoints Newsendpts.comNewsPharmaR and DTrending
#CannesLions2022: Addressing clinical trial diversity problems will take 'real work now,' panelists say,CANNES — As a young scientist, Sommer Bazuro was looking at oncology data when she realized that the patient population was not at all representative of the demographics most likely to suffer and die from cancer. Thinking it must be an isolated incident, she turned to peer-reviewed publications and began Tags:Business and HealthEndpoints Newsendpts.comMarketingNewsPharmapodcasts
#CannesLions2022: Marketing leaders stress importance of empathy in data use,CANNES — With the rise of big data, consumer health marketers are gathering more information about their audiences than ever before. However, experts at this year’s Cannes Lions festival have a warning for creatives: Don’t lose that human touch. “We are all charged with making our brands more empathetic. But Tags:Business and HealthEndpoints Newsendpts.comMarketingNewsPharmapodcasts
#CannesLions2022: Why does diversity matter in creativity? Olympic gold medalist and VMLY&R explain,CANNES – When Olympic gold medalist Tianna Bartoletta went to the hospital to deliver her son last year, she packed signed advanced directives and her will in her bag. Why? Her past experience with the healthcare system while training for the 2020 Toyko Olympics. She was training in sprint and Tags:Business and HealthEndpoints Newsendpts.comFeaturedMarketingNewsPharma
#JPM23 kicks off with an acquisition as Chiesi inks all-cash $1B+ deal for Amryt,As many of the industry’s bigwigs arrive in the Bay Area to hash out deals, Chiesi Farmaceutici is showing up with an all-cash acquisition in the bag. The Italian drug developer said Sunday it is buying rare disease biotech Amryt Pharma for $1.25 billion. Amryt is the maker of four Tags:Business & HealthDealsEndpoints Newsendpts.comPharma
#JPM23 with Robert Nelsen: Our motto is 'do cool [email protected]*t',Endpoints founder John Carroll sat down with ARCH managing director Robert Nelsen during JP Morgan to talk about innovation, what's getting funded and what's ahead in 2023. This transcript has been edited for brevity and clarity. John Carroll: I'm here with Bob Nelsen, one of the co-founders of ARCH. Bob Tags:Business & HealthEndpoints Newsendpts.compremium
#JPM23: Did the IRA kill that drug?,Pharma companies were loud and clear ahead of the passage of Medicare price setting legislation in the Inflation Reduction Act: Once passed, drugs that no longer worked in the new math of the legislation would need to be cut. And within weeks of the law being enacted, we began to Tags:Business & HealthEndpoints Newsendpts.compremium
#JPM23: Fireside chat with Barry Greene: 'There's no straight line to success',Endpoints News founder John Carroll sat down during JP Morgan with Sage CEO Barry Greene to talk about all things neuro. This transcript has been edited for brevity and clarity. John Carroll: Barry Greene, the CEO of Sage Therapeutics, who after a 17-year run at Alnylam jumped and ended up Tags:Business & HealthEndpoints Newsendpts.compremium
#JPM23: When will the IPO window open? What terms are startups getting? Here's what to expect from capital markets this year,Executive Editor Drew Armstrong sat down with Bayer's business development leader Marianne De Backer, PwC's pharma deals chief Roel Van den Akker, and Sofinnova Investments General Partner Maha Katabi to talk about the IPO environment, trends in public and private fundraising, how negotiations between companies have changed and where capital Tags:Business & HealthEndpoints Newsendpts.compremium
2022 was about execution. Now will Amgen's growth strategy prove its worth?,Four of Amgen's top drugs all saw record sales last quarter and strong annual growth, but the California-based biopharma company still has more than a couple remaining question marks to resolve moving into 2023 and beyond. In its Q4 earnings report yesterday, execs highlighted the success of its osteoporosis drug Tags:Business & HealthEndpoints Newsendpts.comPharma
4D Molecular pauses enrollment in Fabry trials after kidney problems in three patients,4D Molecular Therapeutics said it has stopped enrolling patients in its two clinical trials of a gene therapy being investigated for Fabry disease. The biotech will wait until the second half to evaluate 12-month clinical data on the six patients enrolled on 4D-310. The two trials, one in the US Tags:Business & HealthCellGene TxEndpoints Newsendpts.comR&D
A biomanufacturing site is coming to Canada’s Prince Edward Island,Prince Edward Island may be known more to readers of the Anne of Green Gables series of books, but a new effort by the local and national authorities looks to turn the picturesque island into a hub for biomanufacturing and biotech activity. The governments of Canada and Prince Edward Island Tags:Business & HealthEndpoints Newsendpts.comManufacturingPharma
A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test,Issi Rozen is as deeply embedded into the gene editing field as anyone in the buzzy Cambridge, MA biotech hub. As chief business officer and strategy chief for the Broad over a decade-long stretch, he’d worked with all the big names in a scientific discipline that promises to upend the Tags:BioregnumBusiness & HealthCellGene TxEndpoints Newsendpts.comfinancingpremium
A longtime tracker on pharma R&D productivity takes a post-pandemic plunge back to a bleak reality,So much for the “turnaround.” The biopharma industry tossed the old playbook on R&D, broke every rule and bent every trend during the pandemic. Some of the players were rewarded with massive windfalls. And now that Covid-19 isn’t forcing radical change, some of the old trends are back. With a Tags:BioregnumBusiness & HealthEndpoints Newsendpts.compremiumR&D
A NASH biotech plans $75M offering, Arrowhead nabs Amgen payment and Astria raises $115M,A NASH biotech plans $75M offering, Arrowhead nabs Amgen payment and Astria raises $115M,Terns Pharmaceuticals saw its stock $TERN climb 30% on Monday on the back of Madrigal Pharmaceuticals' Phase III win in NASH — which itself likely entered the record books for a single-day stock $MDGL gain of 268% — and the biotech is seeking $75 million to bankroll its own work Tags:Business and HealthEditor's PicksEndpoints Newsendpts.comfinancingNews
A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it,Alfredo Najá Domingos’ prostate cancer was spreading. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. But there was a new treatment he could try: a targeted radiotherapy called Pluvicto — if he could Tags:Business & HealthEndpoints Newsendpts.comIn FocuspremiumR&D
Three ways moving on from Aaron Rodgers impacts Packers
Three ways moving on from Aaron Rodgers impacts Packers,Moving on from a franchise quarterback is a challenging situation for any NFL team. Here are three ways the Packers will be impacted if Rodgers has indeed played his last game as a member of the
DOH warns vs eating seafood from oil spill areas
DOH warns vs eating seafood from oil spill areas,The Department of Health warned the public yesterday against eating fish and other seafood from areas affected by the oil spill.
The post DOH warns vs eating seafood from oil spill areas appeared first
Washington turns to Wall Street to help rescue dying bank
Washington turns to Wall Street to help rescue dying bank,In a scene reminiscent of the last financial crisis, the federal government turned to Wall Street this week for help with a blossoming emergency in the banking sector
The Faroe Islands is some place to die: Daniel Craig's James Bond gets his own gravestone,Daniel Craig’s final James Bond film, No Time to Die, came out last year, and the Faroe Islands — the location for the movie’s memorable villain’s lair — is marking the end of Daniel Craig’s time as Bond with a proper gravestone. Tags:Daniel CraigJames BondMoviesNewsNo Time to DieSYFY Official SiteSYFY WIRE Blog Postsyfy.comSYFYWIRE
'Night Sky': J.K. Simmons & Sissy Spacek hide a galactic secret in trailer for new Amazon sci-fi series,If you ever find a portal to another planet in your backyard, be sure to keep it under wraps for as long as possible. You never know what shady elements might be looking to exploit it for their own nefarious ends. It's the very predicament facing the characters of Night Sky — a new Amazon series debuting on Prime Video late next month. Tags:amazon primeJ.K. SimmonsNewsSci FiScience FictionSissy SpacekSYFY Official SiteSYFY WIRE Blog Postsyfy.comSYFYWIRETrailerstv
Lucy in the sky, with diamond-like stars,One space mission I am avidly keeping track of is Lucy, which launched last October. It’s headed out to Jupiter’s orbit — not Jupiter itself, but its orbit — to pass by quite a few asteroids that share their path with the giant planet. In one sense it’s the most ambitious asteroid mission ever created: It will take close-up images of at least seven asteroids! Tags:AsteroidsBad AstronomyFeaturesjupiterlucyScienceSYFY Official SiteSYFY WIRE Blog Postsyfy.comSYFYWIREtrojans
/cdn.vox-cdn.com/uploads/chorus_asset/file/23262931/jtuohy_220217_5036_0013.jpg "Alexa is getting some much-needed smart home upgrades")
/cdn.vox-cdn.com/uploads/chorus_asset/file/13450357/Tetris.Effect.10.29.Journey.Mode.Metamorphosis.png "Tetris Effect is perfect for people overwhelmed by modern video games")
